| setanaxib (GKT831) / Calliditas |
| Terminated | 2 | 92 | | | Baker Heart and Diabetes Institute, Juvenile Diabetes Research Foundation (JDRF). Australian Type 1 Diabetes Clinical Research Network research grant, Baker Heart and Diabetes Institute, Genkyotex S.A. | diabetic kidney disease, type 1 diabetes | | | | |
2021-004627-33: A research study to investigate the safety of setanaxib and helpfulness in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Estudio para investigar la seguridad de setanaxib y su influencia en el tratamiento del carcinoma escamoso de cabeza y cuello recurrente o metastásico (CECC) |
|
|
| Not yet recruiting | 2 | 70 | Europe | Setanaxib, GKT137831, Tablet | Genkyotex Suisse SA, Calliditas Therapeutics Suisse SA, Calliditas Therapeutics AB | Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Carcinoma escamoso de cabeza y cuello recurrente o metastásico (CECC), Cancer that occurs in the outermost surface of the skin or in certain tissues within the head and neck region including the throat, mouth, sinuses and nose Cancer localizado en la superficie externa de la piel o en ciertos tejidos dentro del área de la cabeza y el cuello incluyendo la garganta, boca, senos y nariz., Diseases [C] - Cancer [C04] | | | | |
| Recruiting | 2 | 60 | US | Placebo Oral Tablet, GKT137831 | University of Alabama at Birmingham, Temple University, Tulane University, University of Michigan | Idiopathic Pulmonary Fibrosis | 11/24 | 01/25 | | |
| Active, not recruiting | 2 | 55 | Europe, US | Setanaxib, Pembrolizumab, Keytruda, Placebo | Calliditas Therapeutics Suisse SA, Calliditas Therapeutics AB | Squamous Cell Carcinoma of Head and Neck | 02/24 | 11/25 | | |
| Completed | 2 | 76 | Europe, Canada, US, RoW | Setanaxib, Placebo | Calliditas Therapeutics Suisse SA | Primary Biliary Cholangitis, Liver Stiffness | 05/24 | 07/24 | | |
NCT06274489: A Study to Evaluate Setanaxib in Patients With Alport Syndrome |
|
|
| Recruiting | 1/2 | 18 | Europe, RoW | Setanaxib, Placebo | Calliditas Therapeutics AB | Alport Syndrome | 01/25 | 01/25 | | |
| Tarpeyo (budesonide) / Calliditas, Stada |
NefXtend, NCT06712407: Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients with Primary IgA Nephropathy |
|
|
| Not yet recruiting | 4 | 60 | NA | TARPEYO®, delayed-release budesonide capsules | Calliditas Therapeutics AB, Worldwide Clinical Trials | IgA Nephropathy | 05/26 | 11/27 | | |
| Completed | 3 | 365 | Europe, Canada, US, RoW | Nefecon, Budesonide modified released capsule, Placebo oral capsule, Placebo | Calliditas Therapeutics AB | Primary IgA Nephropathy | 07/23 | 07/23 | | |
| Completed | 3 | 119 | Europe, Canada, US, RoW | Nefecon 16mg daily | Calliditas Therapeutics AB | Primary IgA Nephropathy | 02/24 | 02/24 | | |
NCT05534919: Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301 |
|
|
| Completed | 3 | 21 | RoW | Nefecon | Everest Medicines (Singapore) Pte. Ltd. | Primary Immunoglobulin a Nephropathy (IgAN) | 07/24 | 07/24 | | |
NCT06589752: Replication of the NefIgArd Trial of TRF-budesonide in Primary IgAN |
|
|
| Completed | N/A | 200 | RoW | TARPEYO 4 MG Delayed Release Oral Capsule, RAS inhibitor | Ruijin Hospital | Primary IgA Nephropathy | 09/24 | 09/24 | | |
| Novel NOX inhibitors / Calliditas |
| No trials found |
| GKT901 / Calliditas |
| No trials found |
| NOX1 inhibitor / Calliditas |
| No trials found |
